sinc
sever
enzym
immunoassaybas
method
approv
primari
donor
screen
test
detect
hivspecif
antibodi
three
addit
test
system
includ
western
blot
analysi
indirect
immunofluoresc
approv
confirmatori
test
infect
character
acut
primari
phase
patient
exhibit
wide
rang
flulik
symptom
period
seroconvers
typic
follow
period
mark
end
preseroconvers
window
howev
incub
time
may
vari
wide
day
month
seroconvers
may
occur
week
longterm
asymptomat
phase
characterist
latent
lowlevel
persist
infect
typic
follow
seroconvers
estim
residu
risk
among
us
blood
donor
eg
probabl
donor
donat
preseroconvers
window
suggest
dramat
decreas
sinc
introduct
donor
hiv
protocol
approxim
per
donor
per
donor
screen
blood
plasma
donor
hcv
implement
follow
identif
viru
respons
major
case
nona
nonb
viral
hepat
develop
analytespecif
reagent
base
viral
antigen
firstgener
test
base
singl
peptid
subsequ
improv
introduc
two
test
util
multipl
peptid
antibodi
captur
approv
analys
differ
version
test
compar
indic
increment
modif
improv
assay
perform
preseroconvers
window
hcv
rel
long
averag
approxim
day
infect
donor
typic
unawar
infect
symptom
evid
period
despit
fluctuat
viral
load
sometim
exceed
copi
viral
genomeml
condit
contribut
elev
residu
risk
per
us
volunt
blood
donor
associ
preseroconvers
window
convent
paradigm
routin
detect
activ
viremia
human
blood
plasma
establish
approxim
year
ago
implement
radioimmun
assay
ria
specif
hbv
surfac
antigen
hbsag
initi
refer
australia
au
antigen
hepatitisassoci
antigen
associ
viral
marker
transmiss
infecti
hepat
plasmabas
therapi
gener
interest
infecti
viral
particl
partit
plasma
fraction
process
abil
analyz
partit
pathogen
track
defin
marker
creat
new
opportun
design
fraction
purif
process
pathogen
safeti
primari
consider
moreov
systemat
detect
hbsag
provid
foundat
develop
screen
qualiti
control
strategi
design
improv
qualiti
plasma
prior
product
deriv
detect
hbsag
use
specif
monoclon
polyclon
antibodi
firmli
establish
histori
transfus
medicin
plasma
industri
practic
high
level
empti
viru
particl
addit
high
titer
intact
infecti
viru
particl
mean
detect
surfac
antigen
gener
effect
measur
interdict
donat
donor
acut
phase
infect
initi
effort
develop
implement
screen
test
involv
multipl
technolog
platform
howev
could
satisfi
oper
requir
associ
screen
whole
blood
plasma
unit
assay
reli
solidphas
immunochemistri
detect
hbsag
ria
elisa
gain
earli
favor
tradit
assay
includ
complement
fixat
counterimmunodiffus
method
current
sever
test
system
differ
manufactur
licens
us
fda
use
donor
screen
confirmatori
test
approv
sensit
test
system
pend
although
incid
hbv
infect
vari
significantli
worldwid
repres
studi
us
volunt
blood
donor
indic
infect
rate
per
donor
draw
screen
paradigm
alreadi
establish
hbv
earli
emphasi
place
develop
assay
direct
detect
public
polit
pressur
heighten
sens
urgenc
close
infecti
window
beyond
achiev
implement
antihiv
antibodi
screen
howev
ambigu
surround
outcom
sever
larg
clinic
studi
instil
sens
uncertainti
potenti
benefit
associ
screen
despit
doubt
util
test
field
fda
adopt
screen
interim
measur
facilit
expand
donor
hiv
screen
protocol
howev
region
regulatori
agenc
notabl
associ
europ
japan
declin
adopt
protocol
safeti
benefit
associ
implement
expand
protocol
gener
perceiv
margin
replac
test
effect
screen
technolog
industri
regulatori
goal
recent
licensur
number
nat
test
system
specif
detect
rna
provid
opportun
elimin
test
donor
hiv
screen
protocol
nucleic
acid
sever
properti
make
effect
target
detect
abil
dna
rna
hybrid
complementari
molecul
mean
great
deal
control
exert
assay
specif
target
nucleic
acid
sequenc
known
nat
method
typic
combin
nucleic
acid
hybrid
amplif
technolog
driven
either
enzymat
chemic
achiev
highli
sensit
detect
specif
nucleic
acid
pcr
earliest
wide
recogn
method
appli
detect
limit
quantiti
viral
nucleic
acid
howev
method
offer
altern
technolog
platform
similar
perform
specif
amplif
nucleic
acid
target
system
includ
transcript
mediat
amplif
tma
nucleic
acid
sequenc
base
amplif
nasba
thermophil
stranddisplac
amplif
tsda
ligas
chain
reaction
lcr
branch
dna
assay
bdna
coupl
effici
nucleic
acid
isol
method
technolog
could
provid
foundat
highli
effici
highthroughput
test
platform
nat
method
also
provid
opportun
introduc
economi
highthroughput
test
environ
increas
sensit
associ
nat
method
allow
test
pool
sampl
individu
sampl
need
test
suspect
posit
target
pathogen
vast
major
sampl
neg
pool
strategi
greatli
enhanc
oper
effici
reduc
number
test
sampl
thu
effect
increas
throughput
util
fluoresc
chemiluminesc
detect
chemistri
nat
method
facilit
process
consolid
reduc
assay
time
addit
probespecif
detect
target
differenti
facilit
multiplex
assay
therebi
increas
array
target
reduc
number
test
perform
final
progress
introduct
autom
gradual
reduc
number
laborintens
step
decreas
time
requir
perform
assay
sinc
activ
dialog
underway
among
scientist
blood
plasma
industri
molecular
diagnost
develop
regulatori
agenc
worldwid
concern
introduct
nat
method
protocol
establish
test
bloodborn
viral
pathogen
semiannu
meet
intern
collabor
help
establish
standard
uniform
polici
collabor
develop
intern
standard
nat
method
tabl
ii
provid
basi
variou
region
regulatori
polici
industri
initi
applic
intern
unit
descript
empir
deriv
consensusbas
potenc
rather
put
physic
entiti
enabl
creation
perform
standard
across
multipl
technolog
platform
legisl
guidanc
document
frequent
specifi
perform
standard
variou
region
world
eu
codif
specif
detect
pathogen
viral
nucleic
acid
pool
human
plasma
open
door
new
era
detect
viral
pathogen
plasma
use
manufactur
protein
therapeut
plasma
therapeut
industri
appli
nat
test
hcv
pool
plasma
sampl
compli
european
us
initi
nat
test
also
implement
improv
interdict
remov
hiv
hbv
havcontamin
unit
plasma
inventori
manufactur
stream
nat
method
enhanc
margin
safeti
blood
plasma
product
allow
detect
viral
pathogen
earlier
window
period
achiev
use
current
antigen
antibodi
test
exampl
window
period
associ
antibodi
assay
approxim
day
assay
reduc
window
period
day
applic
nat
assay
rna
reduc
window
period
day
depend
pool
strategi
employ
us
implement
licens
nat
assay
allow
reduct
test
redund
discontinu
test
howev
mani
develop
countri
implement
nat
techniqu
hinder
complex
high
cost
implement
new
test
platform
upgrad
older
one
consist
strong
emphasi
continu
improv
biolog
product
industri
commit
past
decad
test
procedur
complement
viral
remov
inactiv
measur
design
productspecif
manufactur
stream
provid
better
safeti
featur
plasmaderiv
therapeut
protein
earli
plasma
industri
initi
viral
inactiv
studi
eu
committe
proprietari
medicin
product
cpmp
requir
manufactur
blood
plasma
product
implement
viral
inactivationremov
step
process
accord
regulatori
requir
viral
valid
studi
perform
estim
overal
level
viru
reduct
across
manufactur
process
studi
known
amount
viru
deliber
ad
spike
product
intermedi
materi
treat
accord
manufactur
specif
use
benchscal
model
product
process
viru
reduct
calcul
compar
level
viru
infect
remain
end
process
level
start
materi
sinc
manufactur
process
consist
multipl
step
challeng
system
viru
begin
process
sampl
final
product
practic
strategi
would
requir
massiv
amount
viru
someth
difficult
obtain
result
individu
step
process
usual
evalu
break
process
individu
step
technic
reason
also
allow
accur
character
condit
critic
viral
reduct
better
understand
mechan
viral
clearanc
viru
reduct
express
logarithm
scale
overal
viru
reduct
capac
process
defin
sum
log
reduct
factor
individu
step
howev
simpl
summat
individu
reduct
factor
use
measur
viral
safeti
individu
clearanc
step
yield
consid
neglig
includ
overal
clearanc
process
ad
numer
step
low
individu
reduct
factor
ad
step
share
mechan
viru
clearanc
may
overestim
viru
reduct
capac
process
effect
step
one
clear
least
unit
viru
ie
reduct
titer
robust
step
one
clear
viru
regardless
variabl
product
paramet
gener
singl
effect
robust
step
provid
assur
viral
safeti
sever
step
overal
log
reduct
regulatori
author
recommend
incorpor
least
two
effect
step
unrel
clearanc
mechan
manufactur
process
least
one
step
effect
nonenvelop
virus
ideal
pathogen
viru
directli
test
determin
viral
clearanc
valu
howev
clinic
relev
virus
propag
easili
vitro
result
specif
model
virus
similar
physicochem
characterist
use
repres
relev
uncultiv
virus
addit
nonspecif
model
virus
differ
physicochem
characterist
includ
evalu
theoret
capabl
manufactur
process
clear
unknown
undetect
virus
thu
singl
indic
viru
use
assur
viral
clearanc
capac
manufactur
process
known
unknown
virus
instead
test
panel
relev
model
virus
use
valid
studi
determin
capac
viral
reduct
manufactur
process
tabl
iii
short
list
common
model
test
virus
use
viral
valid
studi
mimic
bloodborn
virus
potenti
caus
clinic
infect
cohnoncley
fraction
well
establish
effici
method
allow
multipl
stepwis
extract
therapeut
protein
figur
frozen
plasma
thaw
slowli
centrifug
remov
cryoprecipit
cold
insolubl
plasma
fraction
contain
fibrinogen
factor
viii
fviii
von
willebrand
vwb
factor
solubl
differ
protein
fraction
remain
supernat
effluent
manipul
ad
differ
amount
alcohol
ethanol
chang
temperatur
ph
andor
ionic
strength
condit
alcohol
precipit
fraction
differ
protein
separ
partit
centrifug
filtrat
although
design
specif
viru
remov
fraction
process
possess
vari
capac
clear
virus
viral
valid
studi
help
explain
fviii
concentr
produc
implement
viral
inactiv
measur
becam
contamin
multipl
virus
immunoglobulin
produc
period
never
transmit
hiv
earli
fviii
concentr
deriv
cryoprecipit
viral
valid
studi
show
viral
clearanc
across
initi
precipit
step
gener
cryoprecipit
contrast
immunoglobulin
deriv
fraction
iiiii
undergo
addit
precipit
step
fraction
iii
purifi
product
also
remov
model
nonenvelop
model
envelop
virus
must
emphas
fraction
step
effect
virus
hcv
transmit
immunoglobulin
manufactur
process
reli
entir
fraction
remov
viru
consequ
addit
viral
inactivationremov
step
differ
mechan
action
requir
manufactur
process
assur
viral
safeti
capryl
octano
acid
use
precipit
remov
lipidslipoprotein
purif
process
intraven
immunoglobulin
ivig
acid
condit
treatment
also
inactivatesremov
least
envelop
virus
coupl
depth
filtrat
nonenvelop
virus
also
remov
protein
usual
solubl
water
solut
hydrophil
amino
acid
interact
water
molecul
polyethylen
glycol
peg
inert
nondenatur
watersolubl
polym
precipit
protein
virus
aqueou
solut
exclud
protein
interact
water
exampl
peg
precipit
step
capabl
remov
virus
purif
process
although
tradit
purif
scheme
reli
exclus
alcohol
precipit
mani
newli
develop
process
fviii
immun
globulin
use
chromatographi
step
remov
contamin
includ
virus
howev
complex
biolog
process
stream
chromatographi
typic
use
primari
extract
often
employ
downstream
polish
step
partial
purifi
fraction
chromatograph
method
separ
protein
base
differ
physicochem
characterist
sinc
virus
consist
mani
differ
protein
may
separ
mani
differ
kind
chromatograph
method
affin
chromatographi
use
biolog
ligand
antibodi
cofactor
recogn
bind
complementari
protein
exampl
one
purif
process
fviii
immobil
monoclon
antibodi
specif
captur
fviii
allow
contamin
protein
porcin
parvoviru
ppv
polioviru
small
nonenvelop
virus
pass
ionexchang
chromatographi
use
differ
charg
separ
protein
although
bind
characterist
protein
chromatograph
process
well
understood
viru
bind
consequ
mani
ligand
use
viral
clearanc
rel
gener
bind
properti
involv
combin
ionic
hydrophob
hydrogen
bond
van
der
waal
interact
one
new
ivig
purif
process
chromatographi
step
separ
impur
igg
also
clear
bovin
viral
diarrhea
viru
bvdv
surrog
hcv
ppv
model
human
parvoviru
remov
hiv
pseudorabi
viru
prv
model
human
herp
virus
reoviru
hav
detect
depth
filter
origin
develop
plasma
fraction
industri
replac
asbesto
prefilt
clarifi
filter
basic
consist
diatomac
earth
cellulos
polymer
bind
resin
bind
resin
also
confer
posit
charg
matrix
enabl
filter
function
ion
exchang
chromatograph
medium
depth
filtrat
effect
remov
envelop
nonenvelop
virus
product
ivig
albumin
unlik
chromatographi
step
develop
protein
purif
viru
remov
coincident
viru
retent
filter
nanofilt
develop
specif
remov
virus
virus
larger
pore
size
nanofilt
retain
combin
size
exclus
adsorpt
mechan
smaller
less
rigid
plasma
protein
pass
nanofiltr
perform
rel
mild
physiolog
condit
pressur
ph
osmolar
temperatur
requir
stabil
chemic
agent
result
biolog
integr
product
compromis
advers
biolog
immunolog
reaction
induc
nanofiltr
theori
limit
pore
size
smaller
pore
smaller
virus
retain
howev
sizebas
exclus
appli
plasma
protein
well
virus
current
smallest
plasma
product
pass
easili
filter
nanofiltr
technolog
improv
reason
expect
avail
membran
capabl
separ
virus
small
parvoviru
protein
larg
igg
fviii
solventdeterg
sd
treatment
disrupt
lipid
coat
envelop
virus
consist
gentli
stir
plasma
protein
solut
nonvolatil
organ
solvent
trinbutylphosph
tnbp
deterg
sodium
cholat
sd
treatment
first
licens
fda
consid
breakthrough
viral
safeti
simplic
effect
inactiv
envelop
virus
maintain
high
protein
recoveri
hiv
bvdv
prv
inactiv
detect
sd
treatment
fviii
ivig
process
intermedi
downstream
process
requir
remov
sd
agent
often
exist
step
remov
protein
contamin
main
limit
failur
inactiv
nonenvelop
virus
hiv
hcv
hbv
transmiss
sdtreat
plasma
product
sinc
introduct
sever
case
hav
parvoviru
transmiss
sdtreat
clot
factor
concentr
addit
capac
induc
precipit
section
capryl
also
inactiv
virus
propos
mechan
inactiv
lipophil
nonion
capryl
disrupt
viral
lipid
membran
render
viru
noninfecti
capryl
inactiv
studi
one
new
ivig
process
show
hiv
bvdv
prv
complet
inactiv
exposur
minut
variat
incub
time
temperatur
ph
protein
concentr
capryl
concentr
within
manufactur
specif
affect
viru
inactiv
demonstr
potenti
capryl
treatment
use
robust
altern
sd
treatment
although
commonli
use
manufactur
process
wash
albumin
past
aceton
shown
inactiv
hiv
bvdv
prv
similar
fortuit
util
alcohol
precipit
viru
remov
step
low
ph
incub
serv
two
function
incub
ivig
low
ph
ph
initi
develop
reduc
anticomplementari
activ
avoid
aggreg
permit
intraven
infus
howev
incub
ivig
low
ph
also
inactiv
substanti
amount
envelop
virus
low
ph
final
incub
step
one
ivig
purif
process
hiv
bvdv
prv
inactiv
detect
day
respect
pasteur
heat
aqueou
stabil
protein
solut
develop
world
war
ii
albumin
ship
world
treat
case
shock
case
hiv
hbv
hcv
ever
trace
transfus
pasteur
albumin
pasteur
final
contain
approv
pharmacopei
method
viral
inactiv
albumin
prepar
result
viral
valid
studi
support
virucid
capac
albumin
pasteur
extend
effect
nonenvelop
virus
pasteur
albumin
final
contain
inactiv
envelop
virus
hiv
bvdv
prv
nonenvelop
virus
reoviru
hav
near
detect
contrast
ppv
reduct
achiev
heat
hour
blumel
et
al
confirm
resist
ppv
albumin
pasteur
also
report
parvoviru
unlik
model
anim
viru
inactiv
heat
minut
result
indic
model
viru
ppv
resist
heat
treatment
parvoviru
suggest
effect
pasteur
inactiv
envelop
nonenvelop
virus
albumin
howev
pasteur
presenc
sucros
less
effect
nonenvelop
virus
reoviru
reduct
similarli
recent
report
parvoviru
transmiss
pasteur
immunoglobulin
presenc
stabil
indic
heat
solut
may
effect
elimin
high
concentr
nonenvelop
virus
parvoviru
pressur
steam
vapor
heat
use
treat
coagul
concentr
twostag
vapor
heat
involv
hour
mbar
follow
hour
mbar
inactiv
hiv
tickborn
enceph
viru
prv
equin
rhinopneumon
viru
model
hav
vapor
heat
inactiv
envelop
virus
gener
nonenvelop
virus
includ
hav
treatment
may
inactiv
parvoviru
complet
termin
dri
heat
treatment
final
contain
freez
dri
product
heat
temperatur
rang
vari
length
time
termin
dri
heat
treatment
develop
inactiv
hiv
coagul
factor
concentr
involv
heat
howev
later
studi
show
inactiv
envelop
virus
hbv
hcv
requir
stringent
condit
result
fviii
product
treat
dri
heat
even
higher
temperatur
eg
longer
period
time
eg
hour
treatment
inactiv
signific
level
envelop
nonenvelop
virus
effect
step
depend
residu
cake
moistur
formul
experi
hepat
virus
hiv
led
implement
mani
viral
remov
inactiv
technolog
plasma
fraction
industri
current
magic
bullet
inactiv
virus
process
techniqu
anticip
near
futur
thu
new
product
process
design
contain
orthogon
reduct
step
assur
broad
effect
viru
reduct
within
specif
product
stream
tabl
iv
summar
viral
reduct
across
sever
repres
manufactur
process
overal
global
reduct
across
manufactur
process
calcul
ad
reduct
factor
individu
step
valu
collect
result
method
describ
previou
section
envelop
virus
eu
regulatori
agenc
recommend
manufactur
process
contain
least
two
effect
mechanist
independ
step
clearanc
capac
step
includ
chemic
physic
treatment
precipit
filtrat
integr
inactiv
remov
envelop
virus
shown
tabl
iv
capac
manufactur
process
inactivateremov
envelop
virus
hiv
hcv
hbv
high
clearanc
nonenvelop
virus
parvoviru
hav
difficult
across
manufactur
process
still
signific
reduct
observ
tabl
iv
nonenvelop
viru
reduct
achiev
combin
remov
step
precipit
filtrat
nanofiltr
inactiv
step
pasteur
dri
heat
treatment
group
virus
often
lead
less
sever
clinic
outcom
eu
regulatori
agenc
requir
least
one
effect
reduct
step
presenc
multipl
step
capabl
remov
inactiv
wide
varieti
virus
complet
differ
mechan
provid
greatest
assur
viru
surviv
one
step
clear
anoth
step
howev
viral
inactiv
remov
step
use
implement
properli
product
carri
adher
current
gmp
cgmp
manufactur
plasma
product
made
major
invest
improv
element
critic
product
integr
viral
safeti
facil
equip
design
qualif
valid
process
control
monitor
qualiti
assur
standard
oper
procedur
staff
train
increasingli
rigor
regulatori
inspect
past
decad
also
play
key
role
promot
enforc
cgmp
complianc
industri
epidemiolog
point
view
classic
cjd
transmit
blood
blood
product
case
long
period
time
would
expect
among
frequent
blood
blood
product
recipi
patient
hemophilia
thalassemia
sickl
cell
diseas
howev
rate
classic
cjd
occurr
elev
popul
retrospect
studi
also
conduct
transfus
recipi
donor
later
develop
classic
cjd
classic
cjd
transmiss
detect
vcjd
epidemiolog
data
remain
limit
diseas
short
histori
long
latenc
period
small
number
case
howev
two
case
presumpt
vcjd
transmiss
use
pack
red
blood
cell
report
uk
therefor
vcjd
transmiss
blood
possibl
although
rare
conclus
posit
result
mani
earli
attempt
transfer
cjd
anim
blood
howev
rel
recent
sheep
model
studi
convincingli
demonstr
transmiss
tse
whole
blood
transfus
blood
sampl
collect
preclin
stage
indic
asymptomat
anim
carri
infecti
agent
use
intracerebr
inocul
infect
also
detect
blood
sampl
rodent
tse
model
obviou
solut
manag
cjdrelat
risk
implement
screen
assay
capabl
detect
marker
ill
preclin
stage
us
alon
estim
blood
donor
defer
theoret
risk
vcjd
transmiss
sinc
vcjd
virtual
nonexist
us
donor
loss
could
avoid
accur
screen
test
avail
howev
pathogen
prion
protein
far
evad
detect
blood
sampl
practic
antemortem
screen
test
pathogen
current
avail
hand
grow
practic
use
postmortem
test
exclud
infect
beef
human
consumpt
reduc
risk
transmit
bse
human
popul
thu
indirectli
improv
safeti
blood
blood
product
absenc
reliabl
antemortem
vitro
diagnost
test
cjd
deferr
polici
way
exclud
highrisk
donor
donor
famili
histori
cjd
patient
undergon
certain
medic
procedur
associ
transmiss
cjd
dura
mater
transplant
human
pituitaryderiv
growth
hormon
administr
exclud
decis
also
made
stop
process
uk
plasma
deriv
major
challeng
defer
donor
elev
risk
expos
bse
agent
balanc
theoret
risk
cjd
transmiss
need
stabl
blood
suppli
regulatori
agenc
around
world
recommend
geograph
deferr
polici
polici
mainli
exclud
donor
spent
certain
amount
time
uk
bse
epidem
period
begin
end
us
stringent
criteria
exclud
donor
stay
uk
cumul
month
franc
cumul
year
militari
base
europ
cumul
month
risk
period
us
polici
also
exclud
donor
blood
transfus
receiv
bovin
insulin
prepar
uk
present
australia
japan
defer
donor
spent
month
uk
polici
like
revis
mechan
cjd
transmiss
becom
better
understood
prion
agent
robust
treatment
heat
solvent
deterg
ioniz
radiat
inactiv
virus
reli
upon
elimin
tse
infect
tse
inactiv
achiev
use
extrem
method
treatment
caustic
autoclav
method
also
destroy
biolog
product
interest
therefor
remov
prion
agent
viabl
mean
reduc
theoret
risk
associ
transmiss
tse
plasmaderiv
protein
determin
capac
prion
remov
manufactur
process
prion
clearanc
studi
perform
studi
analog
viral
clearanc
studi
benchscal
model
manufactur
process
use
section
tse
spike
typic
deriv
infect
brain
homogen
high
titer
prion
protein
infect
also
see
section
partit
tse
infect
purif
process
monitor
rodent
bioassay
although
sensit
assay
typic
requir
number
month
complet
altern
sensit
western
blot
assay
develop
use
monitor
partit
proteinas
resist
form
prion
prpre
surrog
marker
tse
infect
correl
clearanc
prpre
infect
plasma
purif
process
demonstr
prion
confirmationdepend
immunoassay
also
develop
use
benchscal
clearanc
studi
separ
prion
protein
entiti
may
accomplish
exploit
prion
structur
solutionst
properti
prion
hydrophob
aggreg
form
prion
protein
often
associ
cellular
compon
membran
aggreg
vari
size
nanomet
micron
depend
sourc
prepar
tissu
desir
therapeut
protein
small
compar
prion
particl
sediment
filtrat
use
remov
prion
impur
use
well
defin
solut
condit
ph
organ
agent
temperatur
promot
aggregationprecipit
prion
remov
use
sediment
filtrat
tabl
v
time
degre
prion
clearanc
reliabl
predict
basi
condit
use
purifi
protein
thu
prudent
practic
evalu
remov
prion
agent
casebycas
basi
reli
analog
one
best
studi
process
prion
clearanc
cohnoncley
fraction
gener
methodolog
process
see
section
lower
temperatur
plasma
increas
alcohol
concentr
make
ph
adjust
select
precipit
class
protein
number
laboratori
investig
inher
abil
cohnoncley
process
remov
spike
prion
protein
infect
cryosepar
fraction
separ
yield
factor
viiivwb
fibrinogenfactor
ix
respect
figur
two
plasma
intermedi
highest
protein
concentr
clearanc
spike
prion
follow
fraction
separ
fraction
iiiii
separ
first
signific
prion
remov
step
effect
volumevolum
alcohol
combin
low
temperatur
centrifug
result
remov
prpsc
respect
effluent
suggest
prion
precipit
aggreg
use
specif
solutionst
condit
fraction
iiiii
clearanc
clearli
benefici
downstream
product
plasma
protein
fraction
albumin
cohnoncley
process
howev
remov
favor
immunoglobulin
product
prion
spike
copurifi
fraction
iiiii
past
start
materi
ivig
process
fortun
step
immunoglobulin
purif
significantli
clear
spike
prion
immunoglobulin
product
exampl
fraction
iii
separ
reli
solut
condit
maintain
solubl
igg
alcohol
low
temperatur
precipit
prion
remov
use
centrifug
sediment
factor
control
precipit
prpsc
cohnoncley
fraction
investig
detail
sever
factor
identifi
control
precipit
prpsc
solut
among
ph
alcohol
content
salt
concentr
paramet
total
protein
concentr
specif
protein
constitu
temperatur
found
less
import
term
precipit
prpsc
new
ivig
product
develop
use
chromatograph
process
major
purif
method
process
prion
effect
precipit
low
ph
presenc
capryl
remov
subsequ
filtrat
step
signific
prion
reduct
factor
valid
step
process
organ
agent
peg
also
use
effect
remov
spike
prion
process
intermedi
one
purif
process
addit
peg
yield
prpsc
remov
util
precipit
coupl
sediment
filtrat
effect
mean
remov
prion
reduc
risk
tse
transmiss
nanofiltr
size
exclusionbas
method
also
demonstr
signific
potenti
remov
prion
exampl
nfp
normal
flow
parvoviru
membran
millipor
billerica
usa
yield
remov
variou
prepar
prion
spike
model
process
solut
similar
remov
valu
measur
use
pall
corp
east
hill
ny
usa
asahi
kasei
pharma
tokyo
japan
nanofilt
chromatographi
method
may
also
effect
remov
prion
variou
degre
issu
relat
investig
prion
remov
use
spike
materi
deriv
rodent
brain
tissu
typic
hamster
prpsc
strain
deriv
sheep
scrapi
use
clearanc
studi
howev
import
establish
hamster
scrapi
valid
model
partit
human
prion
compar
studi
partit
human
sheep
hamster
form
prpsc
conduct
three
plasma
purif
step
chosen
demonstr
low
cryosepar
intermedi
peg
precipit
high
peg
precipit
clearanc
prpsc
hamster
scrapi
spike
model
brief
found
prpsc
deriv
vcjd
classic
cjd
sporad
cjd
gerstmann
sheinker
diseas
human
brain
tissu
partit
quantit
similarli
prpsc
deriv
sheep
hamster
scrapi
data
indic
case
biochem
separ
hamster
scrapi
use
predict
partit
human
speci
prion
prepar
spike
materi
relat
issu
physic
properti
circul
tse
infect
blood
measur
brain
homogen
may
may
ideal
model
endogen
circul
tse
infect
microsom
highli
purifi
prepar
brain
homogen
propos
investig
altern
crude
brain
homogen
rule
membranebound
form
tse
infect
prion
protein
ie
crude
clarifi
microsom
fraction
brain
homogen
result
lowest
remov
measur
spike
studi
highli
purifi
form
fibril
full
length
scrapi
protein
tend
result
high
level
remov
thu
use
less
purifi
fraction
repres
conserv
estim
prion
remov
past
decad
overal
risk
acquir
seriou
viral
diseas
plasmaderiv
protein
reduc
significantli
fact
confirm
transmiss
hbv
hcv
hiv
us
licens
viral
reduc
plasma
deriv
report
recent
year
favor
statu
result
combin
measur
includ
screen
defer
highrisk
donor
test
collect
donat
use
immunoassay
nat
incorpor
valid
viru
remov
inactiv
step
product
process
establish
increasingli
stringent
pathogen
safeti
regul
spite
advanc
risk
pathogen
transmiss
plasma
product
never
assum
nonexist
current
unknown
virus
could
emerg
known
virus
could
redistribut
geograph
mutat
new
strain
develop
test
method
could
use
screen
plasma
requir
time
reduct
risk
larg
reli
viral
remov
inactiv
step
integr
manufactur
process
howev
step
effect
viru
famili
therefor
import
valid
step
viral
clearanc
capac
envelop
virus
robust
clearanc
step
avail
nearli
product
examin
tabl
iv
therefor
predict
confid
emerg
envelop
virus
sever
acut
respiratori
syndrom
sar
monkeypox
west
nile
viru
like
reduc
significantli
manufactur
process
hand
nonenvelop
virus
especi
small
dna
virus
difficult
inactiv
tabl
iv
special
case
pathogen
prion
collect
experiment
data
indic
likelihood
transmiss
plasma
product
extrem
low
assumpt
substanti
fact
transmiss
cjd
plasma
product
human
popul
never
identifi
variou
manufactur
step
capabl
remov
pathogen
prion
end
manufactur
plasmaderiv
biolog
product
continu
implement
new
measur
decreas
potenti
diseas
transmiss
measur
may
includ
addit
test
procedur
new
virus
well
addit
process
step
dedic
sole
remov
virus
prion
eg
nanofiltr
plasmaderiv
therapeut
product
use
treat
lifethreaten
diseas
imper
dilig
area
pathogen
safeti
continu
recent
histori
demonstr
threat
pathogen
transmiss
product
significantli
mitig
appropri
measur
implement
variou
stage
product
life
cycl
